Financing

PsiThera raises $25 million for oral immunology drugs, with AbbVie Ventures joining

PsiThera closed a $25 million round that brings in AbbVie Ventures and Lumination Capital alongside its earlier backers. The money is meant to pick an oral TNF-alpha inhibitor candidate, start the studies needed before human testing, and move its oral TL1A inhibitors into lead optimization.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call